Trials / Terminated
TerminatedNCT00225290
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Double-blind, Placebo-controlled, Randomized Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- TTY Biopharm · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thalidomide(Thado) |
Timeline
- Start date
- 2003-02-01
- First posted
- 2005-09-23
- Last updated
- 2011-10-12
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT00225290. Inclusion in this directory is not an endorsement.